These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8904617)

  • 1. Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist.
    Marder P; Spaethe SM; Froelich LL; Cerimele BJ; Petersen BH; Tanner T; Lucas RA
    Br J Clin Pharmacol; 1996 Oct; 42(4):457-64. PubMed ID: 8904617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist.
    Marder P; Sawyer JS; Froelich LL; Mann LL; Spaethe SM
    Biochem Pharmacol; 1995 May; 49(11):1683-90. PubMed ID: 7786309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The regulation of CD11b integrin levels on human blood leukocytes and leukotriene B4-stimulated skin by a specific leukotriene B4 receptor antagonist (LY293111).
    van Pelt JP; de Jong EM; van Erp PE; Mitchell MI; Marder P; Spaethe SM; van Hooijdonk CA; Kuijpers AL; van de Kerkhof PC
    Biochem Pharmacol; 1997 Apr; 53(7):1005-12. PubMed ID: 9174114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma.
    Evans DJ; Barnes PJ; Spaethe SM; van Alstyne EL; Mitchell MI; O'Connor BJ
    Thorax; 1996 Dec; 51(12):1178-84. PubMed ID: 8994512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
    Tong WG; Ding XZ; Hennig R; Witt RC; Standop J; Pour PM; Adrian TE
    Clin Cancer Res; 2002 Oct; 8(10):3232-42. PubMed ID: 12374694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological effects of a specific leukotriene B(4) receptor antagonist (VML 295) on blood leukocytes, cutaneous inflammation and epidermal proliferation.
    Seegers BA; Andriessen MP; van Hooijdonk CA; de Bakker ES; van Vlijmen-Willems IM; Parker GL; van Erp PE; van de Kerkhof PC
    Skin Pharmacol Appl Skin Physiol; 2000; 13(2):75-85. PubMed ID: 10754455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery of LY293111, a novel, potent and orally active leukotriene B4 receptor antagonist of the biphenylphenol class.
    Sofia MJ; Floreancig P; Bach N; Baker SR; Nelson K; Sawyer JS; Baldwin R; Cockerham SL; Fleisch JH; Froelich LL; Jackson WT; Marder P; Roman CR; Saussy DL; Silbaugh SA; Spaethe SM; Stengel PW
    Adv Exp Med Biol; 1997; 400A():381-6. PubMed ID: 9547580
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
    Jackson WT; Froelich LL; Boyd RJ; Schrementi JP; Saussy DL; Schultz RM; Sawyer JS; Sofia MJ; Herron DK; Goodson T; Snyder DW; Pechous PA; Spaethe SM; Roman CR; Fleisch JH
    J Pharmacol Exp Ther; 1999 Jan; 288(1):286-94. PubMed ID: 9862783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic actions of the second generation leukotriene B4 receptor antagonist LY29311: in vivo pulmonary studies.
    Silbaugh SA; Stengel PW; Cockerham SL; Froelich LL; Bendele AM; Spaethe SM; Sofia MJ; Sawyer JS; Jackson WT
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Apr; 361(4):397-404. PubMed ID: 10763854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation.
    Zhang W; McQueen T; Schober W; Rassidakis G; Andreeff M; Konopleva M
    Leukemia; 2005 Nov; 19(11):1977-84. PubMed ID: 16151469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors.
    Schwartz GK; Weitzman A; O'Reilly E; Brail L; de Alwis DP; Cleverly A; Barile-Thiem B; Vinciguerra V; Budman DR
    J Clin Oncol; 2005 Aug; 23(23):5365-73. PubMed ID: 15939925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel anti-pancreatic cancer agent, LY293111.
    Ding XZ; Talamonti MS; Bell RH; Adrian TE
    Anticancer Drugs; 2005 Jun; 16(5):467-73. PubMed ID: 15846111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells.
    Tong WG; Ding XZ; Talamonti MS; Bell RH; Adrian TE
    Anticancer Drugs; 2007 Jun; 18(5):535-41. PubMed ID: 17414622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation on a novel and specific leukotriene B4 receptor antagonist in the treatment of stable plaque psoriasis.
    Van Pelt JP; De Jong EM; Seijger MM; Van Hooijdonk CA; De Bakker ES; Van Vlijmen IM; Parker GL; Van Erp PE; Van De Kerkhof PC
    Br J Dermatol; 1998 Sep; 139(3):396-402. PubMed ID: 9767282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration.
    Liston TE; Conklyn MJ; Houser J; Wilner KD; Johnson A; Apseloff G; Whitacre C; Showell HJ
    Br J Clin Pharmacol; 1998 Feb; 45(2):115-21. PubMed ID: 9491823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of leukotriene B4 receptor antagonist, LY293111Na, on antigen-induced bronchial hyperresponsiveness and leukocyte infiltration in sensitized guinea pigs.
    Asanuma F; Kuwabara K; Arimura A; Furue Y; Fleisch JH; Hori Y
    Inflamm Res; 2001 Mar; 50(3):136-41. PubMed ID: 11339501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of LY293111Na, a leukotriene B4 receptor antagonist, on the pulmonary neutrophilia and CD11b expression caused by inhalation of a leukotriene B4 aerosol in rhesus monkeys.
    Allen DL; Hoffman WP; Marder P; Matchett MR; Leiter PA; Abbott DL; Wolff RK
    J Pharmacol Exp Ther; 1996 Apr; 277(1):341-9. PubMed ID: 8613940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of LY293111 in combination with gemcitabine in colonic cancer.
    Hennig R; Ding XZ; Tong WG; Witt RC; Jovanovic BD; Adrian TE
    Cancer Lett; 2004 Jul; 210(1):41-6. PubMed ID: 15172119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substance P-regulated leukotriene B4 production promotes acute pancreatitis-associated lung injury through neutrophil reverse migration.
    Li B; Han X; Ye X; Ni J; Wu J; Dai J; Wu Z; Chen C; Wan R; Wang X; Hu G
    Int Immunopharmacol; 2018 Apr; 57():147-156. PubMed ID: 29482159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.